期刊
CURRENT OPINION IN UROLOGY
卷 17, 期 5, 页码 341-346出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MOU.0b013e3282c8c72b
关键词
bladder cancer; diagnosis; surveillance; tumor markers; urothelial carcinoma
资金
- NCI NIH HHS [R01 CA72821-09] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [R01CA072821] Funding Source: NIH RePORTER
Purpose of review Bladder cancer biomarker development has advanced significantly over the last decade, but has not yet been able to make a significant impact in the diagnosis and management of the disease. Many available markers are suitable, but do not meet the expectations of physicians and patients. Patients do not want to compromise accuracy in diagnosing bladder cancer for less-invasive tests. The review highlights the latest developments in bladder cancer biomarkers, including markers developed over the last year, and comments on the high standards placed on these markers which have delayed their widespread implementation into the urologic field. Recent findings New markers described in the last year include soluble Fas, urothelial carcinoma-associated 1 and human chorionic gonadotropin P type 11 genes. The latter two markers represent the contribution of genomic technology to this field. Also described are updates to known markers, including long-term follow-up of hematuria screening, recent studies in DNA methylation for bladder cancer diagnosis and patient perspectives on bladder tumor markers. Summary Biomarkers for bladder cancer have been intensively scrutinized over the last decade, but despite new findings and good performance characteristics, they are currently not accepted in clinical practice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据